Key result
EES cuts TVR ~31% and lowers all-cause mortality versus SES in diabetic patients.
Why the study?
It was unclear which stent among everolimus-eluting stents, sirolimus-eluting stents, and paclitaxel-eluting stents should be preferred for treating diabetic patients.
Does everolimus-eluting stents improve clinical and angiographic outcomes compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients?
Meta-Analysis (n=4,047)
Does everolimus-eluting stents improve clinical and angiographic outcomes compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients?
In diabetic patients undergoing percutaneous coronary intervention, everolimus-eluting stents significantly reduce all-cause mortality, myocardial infarction, and stent thrombosis compared to first-generation sirolimus- and paclitaxel-eluting stents.
Answers are grounded in this paper and cite their sources.
Supports EES over first-generation DES in diabetic PCI; extends meta-analytic evidence of lower mortality and revascularization.
OBJECTIVE: We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. METHODS: A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. RESULTS: EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52-0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26-0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28-0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07-0.51, p = 0.001). CONCLUSION: Among those three types of stents, EES should be the first recommended stent for DM patients.
No takes yet. Share an insight, caveat, or question.
Ouyang et al. (2021) conducted a meta-analysis in Diabetes mellitus (n=4,047). Everolimus-eluting stents (EES) vs. Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) was evaluated on Target vessel revascularization (EES vs SES) (RR 0.69, 95% CI 0.48-0.98, p=0.04). Everolimus-eluting stents significantly reduced the risk of target vessel revascularization (RR 0.69) and all-cause mortality (RR 0.71) compared to sirolimus-eluting stents in diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: